This information is intended for use by health professionals

1. Name of the medicinal product

Diconal Tablets

Dipipanone/Cyclizine 10mg/30mg Tablets

2. Qualitative and quantitative composition

Each tablet contains 10mg of Dipipanone Hydrochloride BP and 30mg of Cyclizine Hydrochloride BP, coloured deep pink, scored and coded F3A'

3. Pharmaceutical form


4. Clinical particulars
4.1 Therapeutic indications

Diconal Tablets are indicated for the management of moderate to severe pain in medical and surgical conditions in which morphine may be indicated.

Cyclizine is effective in preventing nausea and vomiting associated with the administration of narcotic analgesics.

4.2 Posology and method of administration

Adults: The initial dose in all conditions is one tablet every 6 hours. It is unwise to exceed this dose in view of the difficulty in accurately predicting the initial central effects of dipipanone.

Should this dose fail to prove adequate analgesia, as in severe intractable pain or when other potent opioids have been used, it may be increased by half a tablet every six hours.

It is seldom necessary to exceed a dose of 30mg dipipanone given 6-hourly (i.e. 12 tablets in 24 hours).

Children: There is no specific information on the use of Diconal in children. Diconal is very rarely indicated in children and dosage guidelines cannot be stated.

Use in the elderly: There is no specific information on the use of Diconal in elderly patients. In common with opioid drugs, Diconal may be expected to cause confusion in this age group, and careful monitoring is advised. (See Precautions).

4.3 Contraindications

Diconal is contra-indicated in individuals who are hypersensitive to dipipanone or cyclizine.

Diconal is generally contra-indicated in patients with respiratory depression, especially in the presence of cyanosis and excessive bronchial secretions.

Diconal should not be given during an attack of bronchial asthma.

Diconal is generally contra-indicated in the presence of acute alcoholism, head injury and raised intracranial pressure.

Diconal is contra-indicated in individuals receiving monoamine oxidase inhibitors, or within 14 days of stopping such treatment.

Diconal is contra-indicated in patients with ulcerative colitis since in common with other narcotic analgesics it may precipitate toxic dilatation or spasm of the colon.

As with all narcotic analgesics Diconal should not be administered to patients with severe hepatic impairment as it may precipitate hepatic encephalopathy.

In severe renal impairment Diconal, in common with all narcotic analgesics, may precipitate coma and should not be administered.

Diconal, in common with morphine and most other narcotics, may cause spasm of the biliary and renal tracts; it is contra-indicated in these conditions.

4.4 Special warnings and precautions for use

The repeated use of Diconal may lead to tolerance and physical dependence as well as to psychological dependence on the product.

Misuse of Diconal has been reported, particularly by young addicts who have previously been dependent on, or have misused other agents both opiate and non-opiate. Extreme caution is warranted when prescribing Diconal to this group of patients.

Diconal should be used with extreme caution in the presence of the following: hypothyroidism; adrenocortical insufficiency; prostatic hypertrophy; hypotension secondary to hypovolaemic shock; diabetes mellitus.

Diconal is metabolised in the liver and excreted along with its metabolites in the urine. Where not contra-indicated in patients with impaired hepatic and/or renal function, Diconal should be given at less than the usual recommended dose, and the patient's response used as a guide to further dosage requirements.

Extreme caution should be exercised when administering Diconal to patients with phaeochromocytoma, since hypertension has been reported in association with other potent opioids.

No data are available as to whether or not dipipanone has carcinogenic, mutagenic or teratogenic potential. It is not known whether cyclizine has carcinogenic or mutagenic potential. Some animal studies are interpreted as indicating that cyclizine may be teratogenic, but relevance to the human situation is not known.

In a study involving prolonged administration of cyclizine to male and female rats, there was no evidence of impaired fertility after continuous treatment for 90-100 days. There are no similar data for dipipanone. There is no information on the effect of Diconal on human fertility.

4.5 Interaction with other medicinal products and other forms of interaction

The central nervous system depressant effects of Diconal may be increased by phenothiazine drugs, alcohol, sedatives and tricyclic antidepressants. Concurrent administration of some phenothiazines increases the respiratory depressant effects of narcotic analgesics and also produces hypotension.

Because of its anticholinergic activity, cyclizine may enhance the side effects of other anticholinergic agents.

Analgesic effects of opioid drugs tend to be enhanced by co-administration of dexamphetamine, however their use in combination is not recommended.

4.6 Pregnancy and lactation

The use of Diconal during pregnancy is not recommended. No data are available on the therapeutic use of Diconal in human pregnancy. It may be anticipated that if given in the last trimester, Diconal would cause withdrawal symptoms in the neonate.

Diconal is not recommended for use in labour because of its potential to cause respiratory depression in the neonate.

No data are available on the excretion of dipipanone, cyclizine or their metabolites in human milk.

4.7 Effects on ability to drive and use machines

In common with other opioids, dipipanone may produce orthostatic hypotension and drowsiness in ambulatory patients. Sedation of short duration has been reported in patients receiving intravenous cyclizine. The CNS depressant effects of Diconal may be enhanced by combination with other centrally acting agents (see Interaction with other medicaments and other forms of interactions).

This medicine can impair cognitive function and can affect a patient's ability to drive safely. This class of medicine is in the list of drugs included in regulations under 5a of the Road Traffic Act 1988. When prescribing this medicine, patients should be told:

• The medicine is likely to affect your ability to drive

• Do not drive until you know how the medicine affects you

• It is an offence to drive while under the influence of this medicine

However, you would not be committing an offence (called 'statutory defence') if:

o The medicine has been prescribed to treat a medical or dental problem and

o You have taken it according to the instructions given by the prescriber and in the information provided with the medicine and

o It was not affecting your ability to drive safely

4.8 Undesirable effects

The adverse effects of dipipanone are common to all opioid agents, and may include: respiratory depression; mental clouding, drowsiness and sedation, confusion, mood changes, euphoria, dysphoria, psychosis, restlessness, miosis and raised intracranial pressure; constipation, nausea and vomiting; sweating, facial flushing and hypotension; urticaria and rashes; difficulty with micturition; biliary and renal tract spasm; vertigo.

In addition, cyclizine may cause urticaria, drug rash, drowsiness, dryness of the mouth, nose and throat, blurred vision, tachycardia, urinary retention, constipation, restlessness, nervousness, insomnia and auditory and visual hallucinations, particularly when dosage recommendations have been exceeded. Other central nervous system effects which have been reported rarely include dystonia, dyskenesia, extrapyramidal motor disturbances, tremor, twitching, muscle spasms, convulsions, disorientation, dizziness, decreased consciousness and transient speech disorders. Cholestatic jaundice has occurred in association with cyclizine. Single case reports have been documented of fixed drug eruption; generalised chorea; hypersensitivity hepatitis and agranulocytosis.

4.9 Overdose

The signs of overdosage with Diconal are typically those of opioid poisoning i.e. respiratory depression, pin-point pupils, hypotension, circulatory failure and deepening coma. Mydriasis may replace miosis as asphyxia intervenes. Drowsiness, floppiness, miosis and apnoea have been reported in children, as have convulsions.

General supportive measures should be employed as required. Gastric lavage should be performed if indicated. The specific opioid antagonist naloxone is the treatment of choice for the reversal of coma and the restoration of spontaneous respiration; the literature should be consulted for details of appropriate dosage. Patients should be monitored closely for at least 48 hours after recovery in case of relapse, since the duration of action of the antagonist may be substantially shorter than that of dipipanone.

5. Pharmacological properties
5.1 Pharmacodynamic properties

The onset of analgesic action of dipipanone is approximately one hour and lasts for 4 to 6 hours. Cyclizine produces its anti-emetic effect within 2 hours and lasts for approximately 4 hours.

5.2 Pharmacokinetic properties

Dipipanone is absorbed from the gastrointestinal tract. It is metabolised in the liver and excreted in the urine and faeces, although data on the proportions of parent compound and metabolites so excreted are lacking.

In healthy adult volunteers, the administration of a single oral dose of 50mg cyclizine resulted in a peak plasma concentration of approximately 70nanogram/ml occurring approximately 2 hours after drug administration. The plasma elimination half-life was approximately 20 hours.

The N-demethylated derivative, norcyclizine, has been identified as a metabolite of cyclizine. Norcyclizine has little antihistaminic (H1) activity compared with cyclizine and has a plasma elimination half life of approximately 20 hours. After a single oral dose of 50mg cyclizine given to a single adult male volunteer, urine collected over the following 24 hours contained less than 1% of the total dose administered.

5.3 Preclinical safety data

No additional data of relevance

6. Pharmaceutical particulars
6.1 List of excipients



Dye (FD and C Red No. 3)


Magnesium stearate

6.2 Incompatibilities

None stated

6.3 Shelf life

60 months

6.4 Special precautions for storage

Store below 25°C

Protect from light

Keep dry

6.5 Nature and contents of container

PVC/aluminium foil blister packs containing 50 tablets

6.6 Special precautions for disposal and other handling

None stated

7. Marketing authorisation holder

Amdipharm UK Limited

Regency House

Miles Gray Road



SS14 3AF

United Kingdom.

8. Marketing authorisation number(s)

PL 20072/0009

9. Date of first authorisation/renewal of the authorisation


10. Date of revision of the text